Introduction
Uterine leiomyomas affect up to 30% of reproductive-aged women and they represent the most common gynecologic neoplasm in females.
1,2 Diagnosis of classic uterine leiomyomata by radiology is not complex given their typical features on imaging and clinical manifestations.
Ultimately, tissue diagnosis is definitive when leiomyoma is suspected on radiological imaging to distinguish it from leiomyosarcoma or other neosplasms. Leiomyomas are hormone-driven and most commonly arise from the uterus, but uncharacteristically can originate in the vulva, ovaries, bladder, and urethra. 3 In addition, on rare occasions, they have been discovered in the tissues of bone, deep soft tissues, skin, mediastinum, skeletal and cardiac muscle, lymph nodes, omentum, mesentery, and retroperitoneum. 4 Metastasis of uterine fibroids are rare events and have been given such names as benign metastasizing leiomyoma (BML), intravenous leiomyomatosis (IVL), disseminated peritoneal leiomyomatosis (DPL), retroperitoneal leiomyomatosis (RPL), and parasitic leiomyoma (PL). 3 Multiple mysterious pulmonary nodules resulting from BML were first described by Marshall and Morris 5 and Steiner. 6 BML can be observed as a mass with histologically benign features, but also can demonstrate metastatic potential and present with diffuse lung tumors. This rare disease has gone by many titles. However, the current term, 'benign metastizing leiomyoma', 2 represents a contraindication in the nomenclature. Steiner 6 recommended the use of the term "metastasizing fibroleiomyoma", as he thought the label of "benign" was incorrect.
Intravenous leiomyomatosis (IVL) is historically more rare than BML. 7 Even more of an oddity, IVL can extend into the cardiopulmonary system including the right atrium, right ventricle, and pulmonary arteries. When this extension of these lesions into the cardiac system is present, IVL is termed intracardiac leiomyomatosis (ICLM). In 1974, ICLM was first reported in English. 8 Likely due to technological advancements in imaging techniques, ICLM is being reported more often. However, definitive diagnosis is determined by postoperative pathological evaluation. IVL with cardiac extension is histologically benign. Thus, necrosis, mitoses, or cellular irregularities are rare. (i.e., right atrium). Considering the patient's history, presentation, tissue histopathology, and symptom progressions, the etiology of her disease was determined to be most likely due to IVL.
After the patient's multiple surgical interventions and stability were confirmed, she was discharged and followed as an outpatient. Recently, the patient's tumor tissue specimens were analyzed with the genomic sequencing assay Foundation® to determine if the etiology of this condition could be due to somatic and/or environmental mutations. Testing identified three variants of unknown significance: EGFR:V674I, ERBB4:K1002R, and TSC2:L826M.
Discussion
Pathogenesis and Clinical Findings. Uterine leiomyomas are the most common gynecological tumor in women of reproductive age. 1,2 These tumors typically are benign entities but uncommonly can make transitions toward tissues of malignant potential. Rare growth patterns of uterine leiomyomata have been observed, which include BML, IVL, DPL, RPL, and PL. 3 The pathogenesis of these rare growth patterns is unclear. Furthermore, it remains uncertain which atypical growth pattern predominates over the others, due to all of their individual rarity.
Based on the literature, BML, DPL and RPL has been observed to be more indolent. 3, [10] [11] [12] [13] In contrast, IVL has more aggressive characteristics. 9 The most common findings in patients diagnosed with BML are single or multiple subcentimetric lung nodules with or without a concomitant diagnosis of uterine fibroids, DPL, or IVL. The pathogenesis of BML is remains unclear. However, it has been postulated BML spreads hematogenously, originates from independent multiple foci, and/or is hormone-driven. 3, [10] [11] [12] [13] Other atypical growth patterns that have been found to be hormone-driven include DPL, RPL, and PL. IVL has the unique feature of being incompletely hormone-driven. Clinical and pathological findings characteristic of IVL consist of in intraluminal growth in uterine and/or systemic veins, cord-like vessel lesions, and intracardiac extension, and tricuspid valve insufficiency. 3, [10] [11] [12] [13] The pathogenesis of these atypical growth patterns of uterine leiomyoma is unclear and controversial. These growth patterns are the result of clonal expansion of smooth muscle cells of the uterus, without significant cellular atypia or high mitotic index. 14, 15 In contrast, 6 leiomyosarcomas frequently exhibit the higher turnover rates and atypia. In addition, they rarely are seen with frequency rates of 0.1 to 6%. 16 Primary lesions from these atypical growth patterns could be low-grade, slow growing leiomyosarcomas with inherently intact metastatic potential. 17 Also, erroneous sampling falsely could support the diagnosis of benignity. 18 However, recent cytogenetic studies have refuted this claim by showing that in contrast to leiomyosarcomas, these lesions have identical X-chromosome inactivation and a balanced karyotype. 19, 20 Metastasis of uterine fibroids most commonly appear several years after the diagnosis and removal of uterine leiomyomata by hysterectomy. Thus, prior gynecological surgery such as hysterectomy or myomectomy is a risk factor for developing any of these rare growth patterns that originate from benign uterine fibroids. In our two cases, the interval between uterine fibroid diagnosis, hysterectomy, and metastasis was two and zero years, respectively.
Based on the review of literature, IVL appears to be less common phenomenon. An earlier report reviewing ten cases of BML observed an interval range of four to 23 years (mean 14.9 years) from the time of therapeutic hysterectomy to BML diagnosis. 17 The data remained consistent with preceding case review work that described the interval between hysterectomy to BML diagnosis that ranged from three to 20 years (mean 10 years). 21 We postulate that these variants could be targeted as treatment options in the future when patients have failed all other previous therapies.
Treatment. The benign versus malignant potential of BML and IVL remains unclear.
Currently, there are no definitive guidelines regarding management due to their rare nature. BML is not only reliant on estrogen and progesterone, but also the majority of BML tumors are ER positive. 22 GnRH analogs have been successful in treating BML. 23, 24 Progesterone antagonists have been discussed as possible adjuvant therapy for BML patients, but certain investigators advise against the use of these agents, at least not alone, because of their ability to up-regulate estrogen receptors. 25 Rivera et al. 26 believed anastrozole and raloxifene combination therapy could be as effective as the more traditionally used GnRH agonists and progesterone, even in postmenopausal patients with BML. Based on BML's close relationship to uterine leiomyomas, some investigators are optimistic raloxifene could be a suitable treatment option for BML. The literature is unclear on the effectiveness of tamoxifen on BML lesions. 23, 26 IVL with cardiac extension, such as with the patient in Case 2, has been described in the literature and termed intracardiac leiomyomatosis (ICLM). 8 ICLM is histologically benign.
However, ICLM is suggested to be clinically aggressive due to the risk of sudden death caused 8 by total outflow tract obstruction. Complete removal is the recommended treatment.
Neoadjuvant and adjuvant anti-estrogen regiments or radiation therapy alone have not been
shown to be a curative solution. This is due to the historical nature of IVL tumors to be incompletely hormone-driven. Finally, incomplete removal is not recommended due to previous studies reporting a near 30% recurrence rate if complete removal is not performed.
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